Related references
Note: Only part of the references are listed.Using drug probes to monitor hepatic drug metabolism in critically ill patients: midazolam, a flawed but useful tool for clinical investigation of CYP3A activity?
Chris Kirwan et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2010)
Methadone Pharmacokinetics Are Independent of Cytochrome P4503A (CYP3A) Activity and Gastrointestinal Drug Transport Insights from Methadone Interactions with Ritonavir/Indinavir
Evan D. Kharasch et al.
ANESTHESIOLOGY (2009)
Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity
Evan D. Kharasch et al.
DRUG AND ALCOHOL DEPENDENCE (2009)
Interaction between midazolam and clarithromycin in the elderly
Sara K. Quinney et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities
E. D. Kharasch et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance
E. D. Kharasch et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Limitations of using a single postdose midazolam concentration to predict CYP3A-mediated drug interactions
Scott R. Penzak et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam
E. D. Kharasch et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Drugs as CYP3A probes, inducers, and inhibitors
Yi-Tong Liu et al.
DRUG METABOLISM REVIEWS (2007)
The human cytochrome P450 sub-family: Transcriptional regulation, inter-individual variation and interaction networks
Nick Plant
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2007)
Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers
Emmanuel Krupka et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2006)
New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology
Jeffrey C. Stevens
DRUG DISCOVERY TODAY (2006)
Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: Comparison with ritonavir
KE Culm-Merdek et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Limited sampling models for oral midazolam: Midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity
LS Lee et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam
HN Chaobal et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity
ED Kharasch et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Drug therapy - Drug metabolism and variability among patients in drug response
GR Wilkinson
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Metabolism of alfentanil by cytochrome P4503A (CYP3A) enzymes
TM Klees et al.
DRUG METABOLISM AND DISPOSITION (2005)
Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination
ED Kharasch et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Evidence of significant contribution from CYP3A5 to hepatic drug metabolism
WL Huang et al.
DRUG METABOLISM AND DISPOSITION (2004)
Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: Noninvasive assessment by use of pupillary miosis
ED Kharasch et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity
JC Gorski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice
ML Veronese et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Disposition and miotic effects of oral alfentanil: A potential noninvasive probe for first-pass cytochrome P4503A activity
ED Kharasch et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping
JI Lee et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Single plasma concentrations of 1′-hydroxymidazolam or the ratio of 1′-hydroxymidazolam:midazolam do not predict midazolam clearance in healthy subjects
JF Rogers et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7
JA Williams et al.
DRUG METABOLISM AND DISPOSITION (2002)
Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: Application to various assay techniques
JS Kim et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics - Useful aid to prescribing?
ML Dahl
CLINICAL PHARMACOKINETICS (2002)
A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans
S Phimmasone et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration
YS Lin et al.
PHARMACOGENETICS (2001)
Share Paper
